, Singapore

Biotech firm's COVID-19 detection kit greenlighted for launch

It can now be used directly by laboratories or hospitals to test patients for clinical diagnosis.

Singapore-based biotech firm Veredus Laboratories has obtained the provisional authorisation from Singapore Health Sciences Authority (HSA) for its COVID-19 detection kit.

Dubbed as VereCoV Detection Kit, the device can now be used directly by laboratories or hospitals to test patients for clinical diagnosis. The kit was launched for research use only (RUO) test earlier this year.

It integrates an ultra-fast miniaturised PCR reactor for the amplification of nucleic acids and a customised microarray to qualitatively detect COVID-19 with the additional capability of detecting a subset of Severe Acute Respiratory Syndrome (SARS-CoV) within the same test.

Veredus also mentioned that this was made in collaboration with the Home Team Science and Technology Agency’s (HTX) Chemical, Biological, Radiology, Nuclear and Explosives (CBRNE) Centre of Expertise. 

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.


If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.